{
    "nct_id": "NCT05529849",
    "official_title": "A Two-Part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Subcutaneous Doses of TCMCB07 on Healthy Male and Female Subjects",
    "inclusion_criteria": "* Healthy males and females (WONCBP), aged 18 to 55 years inclusive, at time of signing informed consent.\n* Body mass index 18.0 to 30.0 kg/m2 as measured at Screening or, if outside this range, considered not clinically significant by the investigator.\n* Weight â‰¥ 50 kg at Screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "* Serious adverse reaction or serious known hypersensitivity to melanocortins or polyethylene glycol.\n* Evidence of current severe acute respiratory syndrome coronavirus 2 infection.\n* Clinically significant abnormal clinical chemistry, hematology, or urinalysis as judged by the investigator.\n* Subjects who have received any IP in a clinical research study within 5 half-lives or within 30 days prior to first dose. However, in no event shall the time between last receipt of IP and first dose be less than 30 days.",
    "miscellaneous_criteria": ""
}